Clinical studies have been conducted and specific dosage formulations developed using polymeric microparticles having incorporated therein perfluorocarbon gases that provide significantly enhanced images of long duration. The dosage formulation includes microparticles formed of a biocompatible polym
Clinical studies have been conducted and specific dosage formulations developed using polymeric microparticles having incorporated therein perfluorocarbon gases that provide significantly enhanced images of long duration. The dosage formulation includes microparticles formed of a biocompatible polymer, preferably including a lipid incorporated therein, and containing a perfluorocarbon that is a gas at body temperature. The microparticles are provided to a patient in an amount effective to enhance ultrasound imaging in the ventricular chambers for more than 5 minutes or in the mycocardium for more than a minute, in a dose ranging from 0.025 to 8.0 mg microparticles/kg body weight. Preferably the dose ranges from 0.05 to 4.0 mg microparticles/kg body weight. The dosage formulation typically is provided in a vial. A typical formulation is in the form of a dry powder that is reconstituted with sterile water prior to use by adding the water to the vial or syringe of the dry powder and shaking to yield an isosmotic or isotonic suspension of microparticles.
대표청구항▼
1. A dosage formulation of a dry powder which is reconstituted with a pharmaceutically acceptable carrier for use as an injectable enhanced ultrasound contrast imaging agent, wherein the dosage formulation comprises (a) a container of a defined size for the dry powder,(b) the dry powder comprising a
1. A dosage formulation of a dry powder which is reconstituted with a pharmaceutically acceptable carrier for use as an injectable enhanced ultrasound contrast imaging agent, wherein the dosage formulation comprises (a) a container of a defined size for the dry powder,(b) the dry powder comprising an amount selected from the group consisting of 150-250 mg and 250-1000 mg of dry powdered microspheres comprising a poly(hydroxy acid), copolymer or blend thereof and a hydrophobic compound, wherein the microspheres are porous spheres with a honeycombed structure or sponge-like structure, wherein the microspheres have a mean size ranging from 1.8 to 3.0 microns, and(c) n-perfluorobutane (C4F10) gas,wherein, upon reconstitution of the dry powder in the container by adding a defined amount of the pharmaceutically acceptable carrier suitable for injection, a suspension of microspheres having a concentration ranging from 1.5×109 to 2.8×109 microspheres/mL of suspension or a microsphere mass concentration ranging from 25 to 50 mg microspheres/mL suspension is formed, andwherein the suspension of microspheres provides enhanced ultrasound images of the myocardium for more than one minute. 2. The dosage formulation of claim 1 providing enhanced ultrasound images in the ventricular chambers for at least 30 minutes. 3. The dosage formulation of claim 1, comprising up to 4.0 mg microspheres/kg body weight for a 70 kg person. 4. The dosage formulation of claim 1 comprising sterile water as the pharmaceutically acceptable carrier suitable for injection. 5. The dosage formulation of claim 4 forming a suspension having a microsphere mass concentration ranging from 30 to 45 mg microspheres/mL suspension. 6. The dosage formulation of claim 1, wherein the microspheres have a mean particle size ranging from 1.9 to 2.6 microns. 7. The dosage formulation of claim 1 comprising a dose ranging from 0.5 to 4.0 mg microspheres/kg body weight for a 70 kg person. 8. The dosage formulation of claim 7 wherein the dose is selected from the group consisting of 0.5 mg microspheres/kg body weight, 2.0 mg microspheres/kg body weight and 4.0 mg microspheres/kg body weight for a 70 kg person. 9. The dosage formulation of claim 1 wherein the n-perfluorobutane (C4F10) is provided in an amount between 75 and 500 μg/mL of reconstituted microsphere suspension. 10. The dosage formulation of claim 9 wherein the n-perfluorobutane (C4F10) is provided in an amount between 100 and 400 μg/mL of reconstituted microsphere suspension. 11. The dosage formulation of claim 10 wherein the n-perfluorobutane (C4F10) is provided in an amount between 150 and 350 μg/mL of reconstituted microsphere suspension. 12. The dosage formulation of claim 1, wherein the hydrophobic compound is incorporated with the poly(hydroxy acid), or copolymer or blend thereof at a ratio of between 1 and 12% (weight hydrophobic compound/weight polymer). 13. The dosage formulation of claim 12 wherein the hydrophobic compound is a lipid. 14. The dosage formulation of claim 13 wherein the lipid is a phospholipid selected from the group consisting of dioleoylphosphatidylcholine (DOPC), dimyristoylphosphatidylcholine (DMPC), dipentadecanoylphosphatidylcholine (DPDPC), dilauroylphosphatidylcholine (DLPC), dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), diarachidoylphosphatidylcholine (DAPC), dibehenoylphosphatidylcholine (DBPC), ditricosanoylphosphatidylcholine (DTPC), dilignoceroylphatidylcholine (DLGPC),and phosphatidylethanolamines. 15. The dosage formulation of claim 14, wherein the poly(hydroxy acid) copolymer is poly (lactide-co-glycolide) with a lactide to glycolide ratio of 1:1 and a weight average molecular weight ranging from 20 to 40 kDa, and wherein the lipid is diarachidoylphosphatidylcholine incorporated with the polymer in a range of between 5 and 6.6% (weight lipid/weight poly(hydroxy acid) copolymer). 16. The dosage formulation of claim 1 wherein the container is a vial or syringe. 17. The dosage formulation of claim 16, wherein the vial or syringe further comprises one or more excipients selected from the group consisting sugars, salts, and surfactants. 18. The dosage formulation of claim 1 consisting essentially of one or two doses. 19. The dosage formulation of claim 1 consisting essentially of up to five doses. 20. A kit for enhanced ultrasound contrast imaging comprising (i) an dry powder dosage formulation comprising (a) a container,(b) an amount selected from the group consisting of 150-250 mg and 250-1000 mg of dry powdered microspheres comprising poly(hydroxy acid) or copolymer or blend thereof and a hydrophobic compound,wherein the microspheres are porous spheres with a honeycombed structure or sponge-like structure, wherein the microspheres have a mean size ranging from 1.8 to 3.0 microns, and (c) n-perfluorobutane (C4F10) gas, and(ii) a pharmaceutically acceptable carrier solution suitable for injection for reconstituting the dosage formulation,wherein, upon reconstitution of the dry powder dosage formulation in the container with the pharmaceutically acceptable carrier, a suspension of microspheres having a concentration ranging from 1.5×109 to 2.8×109 microspheres/mL of suspension or a microsphere mass concentration ranging from 25 to 50 mg microspheres/mL suspension is formed,wherein the microspheres provide enhanced ultrasound images for more than one minute in the myocardium, when the microspheres are administered intravenously. 21. The kit of claim 20, wherein the container is a vial or syringe and wherein the kit further comprises a second vial or syringe of a defined amount of the pharmaceutically acceptable carrier for suspending the microspheres. 22. The kit of claim 20, wherein the pharmaceutically acceptable carrier is selected from the group consisting of water for injection, sterile water, saline, saline containing glycerol, saline containing TWEEN® 20, saline containing TWEEN® 80, isosmotic dextrose (5%), ½ isosmotic dextrose (2.5%), isosmotic mannitol (5%), ½ isosmotic mannitol (2.5%), isotonic mannitol containing TWEEN® 20 and isotonic mannitol containing TWEEN® 80. 23. The kit of claim 22, wherein the pharmaceutically acceptable carrier is water for injection. 24. The dosage formulation of claim 1, wherein upon reconstitution with the carrier the suspension of microspheres is in concentration suitable for intravenous administration as a bolus injection.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (204)
Evan C. Unger, Acoustically active drug delivery systems.
Pavia Andre A. (Villeneuve-lez-Avignon FRX) Pucci Bernard (Molleges FRX) Riess Jean G. (Falicon FRX) Zarif Leila (Laurent du Var FRX) Guedj Camille (Pont-Saint-Esprit FRX), Amphiphilic compounds derived from amino acids or peptides, their methods of synthesis and their application as drug del.
Unger Evan C. (13365 E. Camino La Cebadilla Tucson AZ 85749) Wu Guanli (2602 W. Aiden St. Tucson AZ 85749), Apparatus for preparing gas filled liposomes for use as ultrasonic contrast agents.
Long ; Jr. David M. (San Diego CA), Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume.
Long ; Jr. David M. (El Cajon CA), Biocompatible, stable and concentrated fluorocarbon emulsions for contrast enhancement and oxygen transport in internal.
Hilmann Juergen (Berlin DEX) Hoffmann Rolf-Ruediger (Berlin DEX) Muetzel Wolfgang (Berlin DEX) Zimmermann Ingfried (Berlin DEX), Carrier liquid solutions for the production of gas microbubbles, preparation thereof, and use thereof as contrast medium.
Grinstaff Mark W. (Pasadena CA) Soon-Shiong Patrick (Los Angeles CA) Wong Michael (Champaign IL) Sandford Paul A. (Los Angeles CA) Suslick Kenneth S. (Champaign IL) Desai Neil P. (Los Angeles CA), Composition useful for in vivo delivery of biologics and methods employing same.
Tournier Herve (Valleiry FRX) Hyacinthe Roland (Douvaine FRX) Cavagna Friedrich (Romano d\Ezzelino Vicenza ITX), Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients.
Cerny David (Chula Vista CA) Mills Gary J. (San Diego CA) Westkaemper Peter J. (San Diego CA), Continuous sonication method for preparing protein encapsulated microbubbles.
Klaveness Jo (Oslo NOX) Rongved Pal (Hellvik NOX) Solberg Jan (Eiksmarka NOX) Strande Per (Oslo NOX) Wiggen Unni Nordby (Rasta NOX) Redford Keith (Hagan NOX), Contrast agents comprising gas-containing or gas-generating polymer microparticles or microballoons.
Klaveness Jo (Oslo NOX) Rongved Pl (Hellvik NOX) Solberg Jan (Eiksmarka NOX) Strande Per (Oslo NOX) Wiggen Unni Nordby (Rasta NOX) Redford Keith (Hagan NOX), Contrast agents comprising gas-containing or gas-generating polymer microparticles or microballoons.
Klaveness Jo (Olso NOX) Rongved Pl (Hellvik NOX) Stubberud Lars (Sodertalje SEX), Contrast agents, consisting of galactose particles and an amphilic carboxylic acid.
Langer Robert S. (Sommerville MA) Domb Abraham J. (Brookline MA) Laurencin Cato T. (Cambridge MA), Controlled drug delivery high molecular weight polyanhydrides.
Lohrmann Rolf (La Jolla CA) Widder Kenneth J. (Rancho Santa Fe CA) Krishnan Ashwin M. (San Diego CA) Hong Dung K. (San Diego CA) Meng Jialun (San Diego CA), Emulsions as contrast agents and method of use.
Unger Evan C. (13365 E. Camino La Cebadilla Tucson AZ 85749) Wu Guanli (2602 W. Aiden St. Tucson AZ 85745), Gas filled liposomes and their use as ultrasonic contrast agents.
Yan Feng,CHX ; Schneider Michel,CHX ; Brochot Jean,CHX, Gas mixtures useful as ultrasound contrast media contrast agents containing the media and method.
Yan Feng (Carouge CHX) Schneider Michel (Troinex CHX) Brochot Jean (Feigeres FRX), Gas mixtures useful as ultrasound contrast media, contrast agents containing the media and method.
Schrder Ulf (Fagottgrnden 11 B S-223 68 Lund SEX) Mosbach Klaus (Lackalnga 31 S-244 02 Furulund SEX), Intravascularly administrable, magnetically responsive nanosphere or nanoparticle, a process for the production thereof,.
Widder Kenneth J. (8 E. Pearson St. Chicago IL 60611) Senyei Andrew E. (8 E. Pearson St. Chicago IL 60611), Intravascularly-administrable, magnetically-localizable biodegradable carrier.
Schneider Michel (Troinex CHX) Yan Feng (Geneva CHX) Grenier ; deceased Pascal (late of Ambilly FRX by Nadine Garcel ; legal heir ) Puginier Jerome (Le Chable-Beaumont FRX) Barrau Marie-Bernadette (G, Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the prepa.
Schneider Michel (Troinex CHX) Yan Feng (Genve CHX) Grenier ; deceased Pascal (late of Ambilly FRX by Nadine Garcel ; legal heir) Puginier Jrme (Le Chble-Beaumont FRX) Barrau Marie-Bernadette (Geneva, Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the prepa.
Schneider, Michel; Yan, Feng; Garcel, Nadine; Puginier, J?r?me; Barrau, Marie-Bernadette, Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof.
Desai Neil P. (Los Angeles CA) Soon-Shiong Patrick (Los Angeles CA) Sandford Paul A. (Los Angeles CA) Grinstaff Mark W. (Pasadena CA) Suslick Kenneth S. (Champaign IL), Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell.
Church Charles C. ; Bernstein Howard ; Straub Julie Ann ; Brush Henry T., Method for enhancing the echogenicity and decreasing the attenuation of microencapsulated gases.
Grinstaff Mark W. (Pasadena CA) Desai Neil P. (Los Angeles CA) Suslick Kenneth S. (Champaign IL) Soon-Shiong Patrick (Los Angeles CA) Sandford Paul A. (Los Angeles CA) Merideth Noma R. (Pacific Palis, Method for the preparation of fluorocarbon-containing polymeric shells for medical imaging.
Conston, Stanley R.; Yamamoto, Ronald; Ottoboni, Thomas B.; Tickner, E. Glenn, Method for ultrasound triggered drug delivery using hollow microbubbles with controlled fragility.
Lambert Karel J. (San Diego CA) Jablonski Edward G. (Escondido CA) Hulle Carl (San Diego CA), Method of making encapsulated gas microspheres useful as an ultrasonic imaging agent.
Evan C. Unger ; Thomas A. Fritz ; Terry Matsunaga ; VaradaRajan Ramaswami ; David Yellowhair ; Guanli Wu, Method of preparing gas and gaseous precursor-filled microspheres.
Unger Evan C. (Tucson AZ) Fritz Thomas A. (Tucson AZ) Matsunaga Terry (Tucson AZ) Ramaswami VaradaRajan (Tucson AZ) Yellowhair David (Tucson AZ) Wu Guanli (Tucson AZ), Method of preparing gas and gaseous precursor-filled microspheres.
Levene Harold B. (San Diego CA) Villapando Elaine (San Diego CA) Barnhart James L. (Encinitas CA) Widder Kenneth J. (Del Mar CA), Method of ultrasound imaging of the gastrointestinal tract.
Unger Evan C. (13365 E. Camino La Cebadilla Tucson AZ 85749), Methods for providing localized therapeutic heat to biological tissues and fluids using gas filled liposomes.
Grinstaff Mark W. (Pasadena CA) Soon-Shiong Patrick (Los Angeles CA) Wong Michael (Champaign IL) Sandford Paul A. (Los Angeles CA) Suslick Kenneth S. (Champaign IL) Desai Neil P. (Los Angeles CA), Methods for the preparation of nucleic acids for in vivo delivery.
Unger Evan C. (Tucson AZ) Fritz Thomas A. (Tucson AZ) Matsunaga Terry (Tucson AZ) Ramaswami VaradaRajan (Tucson AZ) Yellowhair David (Tucson AZ) Wu Guanli (Tucson AZ), Methods of preparing gas-filled liposomes.
Klaveness Jo (Oslo NLX) Rongved Pal (Hellvik NLX) Stubberud Lars (Sodertalje NLX), Microbubble-generating contrast agents for ultrasound and magnetic resonance imaging.
Bernstein Howard (Cambridge MA) Straub Julie A. (Winchester MA) Brush Henry T. (Somerville MA) Wing Richard E. (Cambridge MA), Microencapsulated fluorinated gases for use as imaging agents.
Tournier Herve (Valleiry FRX) Hyacinthe Roland (Douvaine FRX) Cavagna Friedrich (Vicenza ITX), Mucoadhesive compositions for increasing the ultrasonic image contrast of the digestive tract.
Grinstaff Mark W. (Pasadena CA) Desai Neil P. (Los Angeles CA) Suslick Kenneth S. (Champaign IL) Soon-Shiong Patrick (Los Angeles CA) Sandford Paul A. (Los Angeles CA) Merideth Noma R. (Pacific Palis, Non-fluorinated polymeric shells for medical imaging.
Vassiliades Anthony E. (Deerfield IL) Shroff Shrenik (Lake Forest IL) Nauman Edward F. (Chicago IL), Oil-in-water emulsions containing hydropholeic starch.
Charpiot Brigitte (Nice FRX) Greiner Jacques (Nice FRX) Le Blanc Maurice (Nice FRX) Manfredi Alexandre (Nice FRX) Riess Jean (Falicon FRX) Zarif Leila (Nice FRX), Polyhydroxylated and highly fluorinated compounds, their preparation and their use as surfactants.
Vanderhoff John W. (345 9th Ave. Bethlehem PA 18018) El-Aasser Mohamed S. (1201 N. Maxwell St. Allentown PA 18103) Ugelstad John (SINTEF ; 7034 Trondheim-NTH Trondheim NOX), Polymer emulsification process.
Grinstaff Mark W. (Pasadena CA) Desai Neil P. (Los Angeles CA) Suslick Kenneth S. (Champaign IL) Soon-Shiong Patrick (Los Angeles CA) Sandford Paul A. (Los Angeles CA) Merideth Noma R. (Pacific Palis, Polymeric shells for medical imaging prepared from synthetic polymers, and methods for the use thereof.
Sutton Andrew D. (Ruddington GB2) Johnson Richard A. (West Bridgford GB2) Senior Peter J. (Near Melbourne GB2) Heath David (The Park GB2), Preparation of diagnostic agents.
Couvreur Patrick (Wavre BEX) Roland Michel (Brussels BEX) Speiser Peter (Forch CHX), Preparation of submicroscopic particles, particles thus obtained and pharmaceutical compositions containing them.
Cohan Allan N. (1143 Wright Dr. Huntingdon Valley PA 19006), Process for producing round spherical free flowing blown bead food products of controlled bulk density.
Devissaguet Jean-Philippe (Neuilly sur Seine FRX) Fessi Hatem (Paris FRX) Puisieux Francis (Maisons Alfort FRX), Process for the preparaton of dispersible colloidal systems of a substance in the form of nanocapsules.
Trevino Leo A. ; Schutt Ernest George ; Klein David H. ; Tarara Thomas E. ; Weers Jeffry G. ; Kabalnov Alexey, Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement.
Schutt Ernest G. (San Diego CA) Evitts David P. (La Jolla CA) Kinner Rene Alta (San Diego CA) Anderson Charles David (Lebanon NJ) Weers Jeffry G. (San Diego CA), Stabilized microbubble compositions.
Schneider Michel (Troinex CHX) Bichon Daniel (Montpellier FRX) Bussat Philippe (Collonge S/Saleve FRX) Puginier Jerome (Le Chable-Beaumont FRX) Hybl-Sutherland Eva (Wiesbaden DEX), Stable microbubbles suspensions injectable into living organisms.
Schneider Michel (Troinex CHX) Bichon Daniel (Montpellier FRX) Bussat Philippe (Collonges S/Saleve FRX) Puginier Jerome (Le Chable-Beaumont FRX) Hybl-Sutherland Eva (Wiesbaden DEX), Stable microbubbles suspensions injectable into living organisms.
Schneider Michel (Troinex CHX) Bichon Daniel (Montpellier FRX) Bussat Philippe (Collonges S/Saleve FRX) Puginier Jerome (Le Chable-Beaumont FRX) Hybl-Sutherland Eva (Wiesbaden DEX), Stable microbubbles suspensions injectable into living organisms.
Schneider Michel (Troinex CHX) Bichon Daniel (Montpellier FRX) Bussat Philippe (Collonges S/Saleve FRX) Puginier Jerome (Le Chable-Beaumont FRX) Hybl-Sutherland Eva (Wiesbaden DEX), Stable microbubbles suspensions injectable into living organisms.
Schneider Michel (Troinex CHX) Bichon Daniel (Montpellier FRX) Bussat Philippe (Collonqes S/Saleve FRX) Puginier Jerome (Le Chable-Beaumont FRX) Hybl-Sutherland Eva (Wiesbaden DEX), Stable microbubbles suspensions injectable into living organisms.
Liversidge Gary G. (West Chester PA) Cundy Kenneth C. (Pottstown PA) Bishop John F. (Rochester NY) Czekai David A. (Honeoye Falls NY), Surface modified drug nanoparticles.
D\Arrigo Joseph S. (23A Brickyard Rd. Farmington CT 06032), Surfactant mixtures, stable gas-in-liquid emulsions, and methods for the production of such emulsions from said mixtures.
Unger Evan C. (Tucson AZ) Fritz Thomas A. (Tucson AZ) Matsunaga Terry (Tucson AZ) Ramaswami VaradaRajan (Tucson AZ) Yellowhair David (Tucson AZ) Wu Guanli (Tucson AZ), Therapeutic delivery systems related applications.
Reinhardt Michael (Berlin DEX) Fritzsch Thomas (Berlin DEX) Heldmann Dieter (Berlin DEX) Siegert Joachim (Berlin DEX), Ultrasonic contrast agents for color Doppler imaging.
Erbel Raimund (Mainz DEX) Zotz Rainer (Mainz DEX) Krone Volker (Flrsheim DEX) Magerstdt Michael (Hofheim am Taunus DEX) Walch Axel (Frankfurt am Main DEX), Ultrasonic contrast agents, processes for their preparation and the use thereof as diagnostic and therapeutic agents.
Rasor Ned S. (Cupertino CA) Hilmann Jurgen (Berlin DEX) Lange Lothar (Berlin DEX) Fritzsch Thomas (Berlin DEX) Siegert Joachim (Berlin DEX) Zimmermann Ingfried (Weiler DEX), Ultrasonic contrast medium comprising gas bubbles and solid lipophilic surfactant-containing microparticles and use ther.
Eriksen, Morten; Østensen, Jonny; Frigstad, Sigmund; Rongved, Pål, Ultrasound imaging with contrast agent targeted to microvasculature and a vasodilator drug.
Roth Duane J. (La Jolla CA) Keipert Peter E. (San Diego CA) Faithfull Nicholas S. (Normanton by Bottesford OH GB2) Zuck Thomas F. (Cincinnati OH) Riess Jean G. (Nice FRX), Use of synthetic oxygen carriers to facilitate oxygen delivery.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.